文献速递免疫规划妇幼与学校卫生

COVID-19疫苗接种后妊娠相关不良结局风险:与流感疫苗接种的倾向评分匹配分析

The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
PubMed 文献 · Vaccine · 2024-11-25

本研究利用韩国国民健康保险服务理赔数据库与疫苗接种登记数据,按1:3倾向评分匹配比较仅接种COVID-19疫苗组与仅接种流感疫苗组、以及同时接种两种疫苗组与仅接种流感疫苗组。结果显示仅接种COVID-19疫苗组大于胎龄儿风险高于仅接种流感疫苗组(OR=2.285,95%CI=1.155-4.522,P=0.018),同时接种组早产风险高于仅接种流感疫苗组(OR=1.365,95%CI=1.124-1.656,P=0.002)但低于国内基线发生率,其他母婴结局无显著差异。作者认为孕期mRNA COVID-19疫苗接种是安全的,建议孕妇接种COVID-19疫苗。

要点

  • 仅接种COVID-19疫苗组大于胎龄儿风险高于仅接种流感疫苗组(OR=2.285,95%CI=1.155-4.522,P=0.018)。
  • 同时接种两种疫苗组早产风险高于仅接种流感疫苗组(OR=1.365,95%CI=1.124-1.656,P=0.002)但低于国内基线发生率。
  • 其他母婴结局在两组间无显著差异,作者认为孕期mRNA COVID-19疫苗接种安全并建议孕妇接种。

核心结论

  • 孕期mRNA COVID-19疫苗接种是安全的,未出现母婴不良结局的显著增加。
  • 鉴于孕妇COVID-19高发病率和高死亡率,作者认为推荐孕妇接种COVID-19疫苗是合理的。

研究设计与样本

  • 采用倾向评分匹配队列研究,数据来自国民健康保险服务理赔数据库并结合疾病管理厅COVID-19与流感疫苗接种登记数据。
  • 按年龄、合并症、保险类型、地区、医院类型、接种时孕周及初产进行匹配,仅接种COVID-19疫苗组与仅接种流感疫苗组按1:3匹配,同时接种两组疫苗组与仅接种流感疫苗组也按1:3匹配。
  • 采用逻辑回归分析计算两组间比值比(OR)及95%置信区间(CI)。
  • 2021年10月18日至2022年3月3日期间识别71,902名孕妇,核实67,522人的接种记录。
  • 其中仅接种COVID-19疫苗610人,仅接种流感疫苗49,952人,同时接种两种疫苗2405人。

主要发现

  • 仅接种COVID-19疫苗组大于胎龄儿风险高于仅接种流感疫苗组(OR=2.285,95%CI=1.155-4.522,P=0.018)。
  • 同时接种两种疫苗组早产风险高于仅接种流感疫苗组(OR=1.365,95%CI=1.124-1.656,P=0.002),但低于国内基线发生率。
  • 其他母婴结局未见显著差异。

临床怎么用

  • 作者认为,鉴于孕妇COVID-19高发病率和高死亡率,推荐孕妇接种COVID-19疫苗是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Coronavirus 2019 (COVID-19) vaccination rates in pregnant women remain low owing to safety concerns. When evaluating vaccine safety, comparisons with unvaccinated individuals may lead to healthy vaccinee bias. This study aimed to investigate the association between mRNA-based COVID-19 vaccination and pregnancy-related adverse outcomes compared with influenza vaccination. METHODS: A propensity score-matched cohort study was conducted using the National Health Insurance Service insurance claims database, combined with COVID-19 and influenza vaccination registration data from the Korea Disease Control and Prevention Agency. Based on the age, comorbidities, insurance type, region, hospital type, gestational age at vaccination, and primiparity, the COVID-19 vaccination-only group and influenza vaccination-only group were matched in a 1:3 ratio, while both (COVID-19 and influenza) vaccination group and influenza vaccination-only group were also matched in a 1:3 ratio. Logistic regression analysis was used to calculate odds ratios (ORs) with 95 % confidence intervals (CIs) between the two groups. RESULTS: From October 18, 2021, to March 3, 2022, 71,902 pregnant women were identified, and the vaccination records of 67,522 individuals were verified. Among them, 610 received the COVID-19 vaccination only, 49,952 received the influenza vaccination only, and 2405 received both vaccines. In the COVID-19 vaccination-only group, the risk of large for gestational age was higher than in the influenza vaccination-only group (OR = 2.285, 95 % CI = 1.155-4.522, P = 0.018). In the group that received both vaccinations, the risk of premature birth was higher (OR = 1.365, 95 % CI = 1.124-1.656, P = 0.002) than that in the influenza vaccination-only group but lower than the domestic baseline incidence rates. No significant differences were observed in other maternal and neonatal outcomes. CONCLUSION: mRNA-based COVID-19 vaccination in pregnant women is safe without a remarkable increase in adverse maternal and neonatal outcomes. Given the high morbidity and mortality rates of COVID-19 in pregnant women, it is reasonable to recommend COVID-19 vaccination for pregnant women.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Choi YJ, Jung J, Kang M, et al. The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination. Vaccine. 2024. PMID: 39591703. doi:10.1016/j.vaccine.2024.126506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。